Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Twist Bioscience Corporation

TWSTNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Sep 21, 2026Accepted Sep 21, 2026, 4:05 PM EDTFiling CIK 1581280Accession 0001214659-26-011832
Share

Structured filing — 4

marketforms-74024.xml

Open full document ↗

Filing details

Report period
2026-09-17
Issuer
Twist Bioscience Corp
Issuer CIK
0001581280
Trading symbol
TWST
Rule 10b5-1 indication
Checked

Reporting owner 1

Name
Leproust Emily M.
Reporting owner CIK
0001753655
Relationship
Director · Officer
Officer title
Chief Executive Officer
Address
C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD., SOUTH SAN FRANCISCO, CA, 94080

Non-derivative transactions

Non-derivative transactions · 15 reported rows
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnership
Common Stock2026-09-17M · Form 4[F1]133,269A26.66901,696D
Common Stock2026-09-17M · Form 4[F1]75,439A8.82977,135D
Common Stock2026-09-17S · Form 4[F1]2,440D151.4613[F2]974,695D
Common Stock2026-09-17S · Form 4[F1]6,644D152.2112[F3]968,051D
Common Stock2026-09-17S · Form 4[F1]3,399D153.4031[F4]964,652D
Common Stock2026-09-17S · Form 4[F1]4,175D154.1703[F5]960,477D
Common Stock2026-09-17S · Form 4[F1]13,378D155.4568[F6]947,099D
Common Stock2026-09-17S · Form 4[F1]9,097D156.4674[F7]938,002D
Common Stock2026-09-17S · Form 4[F1]32,260D157.4860[F8]905,742D
Common Stock2026-09-17S · Form 4[F1]232,173D158.0876[F9]673,569D
Common Stock2026-09-17S · Form 4[F1]23,884D159.5315[F10]649,685D
Common Stock2026-09-17S · Form 4[F1]14,493D160.4392[F11]635,192D
Common Stock2026-09-17S · Form 4[F1]11,169D161.4930[F12]624,023D
Common Stock2026-09-17S · Form 4[F1]2,565D162.3136[F13]621,458D
Common Stock2026-09-17S · Form 4[F1]869D163.3926[F14]620,589D
Table key
M · Form 4
Exempt derivative exercise or conversion under Rule 16b-3
A
Acquired
D
Direct
S · Form 4
Sale on the market or privately

Derivative transactions

Derivative transactions · 2 reported rows
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
Employee Stock Option (right to buy)8.822026-09-17M · Form 475,439D0[F18]2027-09-28Common Stock75,4390D
Employee Stock Option (right to buy)26.662026-09-17M · Form 4133,269D0[F19]2028-11-18Common Stock133,2690D
Table key
M · Form 4
Exempt derivative exercise or conversion under Rule 16b-3
D
Direct

Derivative holdings

Derivative holdings · 3 reported rows
SecurityConversion / exercise price (USD)ExercisableExpiresUnderlying securityUnderlying sharesAmount ownedOwnership
Employee Stock Option (right to buy)5.95[F15]2025-09-28Common Stock00D
Employee Stock Option (right to buy)23.33[F16]2029-10-23Common Stock131,290131,290D
Employee Stock Option (right to buy)67.852022-12-192030-08-31Common Stock64,95064,950[F17]D
Table key
D
Direct

Footnotes

F1
The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8↩ 9↩ 10↩ 11↩ 12↩ 13↩ 14↩ 15
F2
Represents the weighted average sales price per share. The shares sold at prices ranging from $150.77 to 151.77 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
F3
Represents the weighted average sales price per share. The shares sold at prices ranging from $151.78 to $152.71 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
F4
Represents the weighted average sales price per share. The shares sold at prices ranging from $152.87 to $153.85 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
F5
Represents the weighted average sales price per share. The shares sold at prices ranging from $153.88 to $154.84 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
F6
Represents the weighted average sales price per share. The shares sold at prices ranging from $154.9 to $155.9 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
F7
Represents the weighted average sales price per share. The shares sold at prices ranging from $155.92 to $156.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
F8
Represents the weighted average sales price per share. The shares sold at prices ranging from $156.96 to $157.96 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
F9
Represents the weighted average sales price per share. The shares sold at prices ranging from $157.97 to $158.96 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
F10
Represents the weighted average sales price per share. The shares sold at prices ranging from $158.99 to $159.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
F11
Represents the weighted average sales price per share. The shares sold at prices ranging from $160.00 to $160.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
F12
Represents the weighted average sales price per share. The shares sold at prices ranging from $161.00 to $161.97 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
F13
Represents the weighted average sales price per share. The shares sold at prices ranging from $162.02 to $163 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
F14
Represents the weighted average sales price per share. The shares sold at prices ranging from $163.03 to $163.6 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
F15
The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.↩ 1
F16
25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.↩ 1
F17
Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.↩ 1
F18
The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.↩ 1
F19
The option is immediately exercisable. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vested and became exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.↩ 1

Signature 1

Signed
/s/ Kendra Fox, as Attorney-in-Fact for Emily M. Leproust
Date
2026-09-21

Company context

At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets. We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal - more experiments, more iterations, more chances for remarkable discoveries.

Current securities

Recent company filings

  1. Results of Operations and Financial ConditionNov 12, 2026
  2. SCHEDULE 13G/A - filed by Artisan Partners Limited Partnership regarding Twist Bioscience CorpNov 12, 2026
  3. SCHEDULE 13G - filed by STATE STREET CORP regarding Twist Bioscience CorpNov 10, 2026
  4. SCHEDULE 13G/A - filed by FMR LLC regarding Twist Bioscience CorpNov 5, 2026
  5. 144 filingSep 21, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.